AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03184766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator 2 Nurofen Immedia 200 mg Weichkapseln, ibuprofen liquid capsules
Description: 2 x 200 mg solubilised ibuprofen
Study NCT03750344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diagnostic test
Description: Comparison of respiratory rates in normal subjects as observational with end tidal CO2. No treatment or interventions will be performed
Study NCT01341925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 Supplementation
Description: The Ω3 group will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3) two times daily for a total daily dose of 2000 mg Ω3 (1400 mg EPA: 200 mg DHA; 400 other Ω3). The placebo group will receive two capsules two times daily matched for odor and appearance with the active intervention.
Study NCT01341925 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational Psychotherapy (PEP)
Description: Therapy sessions occur twice a week for up to 24 sessions of manualized treatment. The importance of separating symptoms from the individual is emphasized. The family is offered support, validation, and recognition for their own difficult experiences in living with the child's mood disorder. Family members are taught that patients are particularly vulnerable to stress and tension; thus, therapists work with families to reduce the level of stress and tension in their homes. Improvement of communication, problem solving and coping strategies can lead to restoration of hope for recovery and decrease family dysfunction. Goals include strengthening the parent-child bond and helping children and parents feel competent to manage depression now and in future recurrences.
Study NCT01341925 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group will receive active monitoring (no IF-PEP) and two capsules two times daily matched for odor and appearance with the active intervention.
Study NCT05084820 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Action observation treatment
Description: Participants will watch 5 videos of motor tasks; each video is of 30 sec and watch for 4 times (i.e. for 2 minutes). Then patient will execute the motor act, soon after the observation with an affected limb for 2 minutes, with total rest time of 5 minutes for this treatment. Conventional treatment of muscle stretching, strengthening and ROM exercises will be given for 15 minutes including rest. Total treatment time is 40 minutes.
Study NCT05084820 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: conventional treatment of 40 minutes in total will be performed including Stretching (for 8-10 sec with set of 5 repetitions/ session on each side for 3 minutes total with rest), strengthening (weighted bicep curls, side arm raise and open arm movement exercises with set of 5 repetitions/ session for 9 minutes total with rest), Range of motion exercises active and passive with set of 5 repetitions/ session for 3 minutes total with rest and gripping,reaching, grasping exercises (on each side for total 25 minutes including rest) with assistance of physiotherapist
Study NCT01476553 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extensive Intraperitoneal Lavage (EIPL)
Description: EIPL is performed after completing resection and lymphadenectomy: the abdominal cavity has to be washed ten times with one liter Ringer's solution. Each liter has to be well dispersed manually in the abdominal cavity, and removed and disposed completely. 100 ml of the last liter of lavage fluid will be harvested and sent for analysis.~Contrary to the Japanese trial, Ringer's solution will be used instead of normal saline solution because of a presumed higher likelihood of peritoneal adhesions when employing the latter (7). Ringer's solution is the standard used for all intraperitoneal lavage procedures at the study centre. To avoid hypothermia, the lavage fluid will be warmed to body temperature (37° Celsius).
Study NCT04942769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selenium
Description: selenium 100ug ，take it orally twice daily
Study NCT01983683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadazolid
Description: Cadazolid 250 mg as oral suspension twice daily.
Study NCT01983683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin 125 mg as oral capsules 4 times daily
Study NCT01983683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cadazolid-matching placebo
Description: Placebo matching cadazolid and administered orally twice daily
Study NCT01983683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin-matching placebo
Description: Placebo capsules matching vancomycin and administered orally 4 times per day
Study NCT03267433 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate
Description: Undergo bone marrow biopsy and aspirate
Study NCT03414268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Micronized dHACM
Description: 1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)
Study NCT03414268 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Injection
Description: Injection of 1mL 0.9% Sodium Chloride Injection, USP
Study NCT04282369 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HHHFNC
Description: noninvasive ventilation modality
Study NCT04282369 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NCPAP
Description: noninvasive ventilation modality
Study NCT04282369 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIPPV
Description: noninvasive ventilation modality
Study NCT04282369 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NHFO
Description: noninvasive ventilation modality
Study NCT01846208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Egg Oral Immunotherapy
Description: Commercially available egg white solid dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.
Study NCT01846208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baked Egg
Description: Predetermined food substances with known amounts of Baked Egg (egg protein) with standardized dosing/consumption instructions.
Study NCT03729908 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animal assisted mindfulness based intervention
Description: A mindfulness based intervention in the presence of an animal
Study NCT03729908 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Anti-stress program
Description: A mindfulness based intervention with no reference to animals
Study NCT03267433 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy and aspirate
Study NCT04255212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodynamic treatment
Description: Participants will be asked to lay supine on a medical table and keep their arms relaxed. 30 repetitions of gentle upper limb nerves mobilization, performed through a combination of neck and arm physiological movements, will be administered with cycles of tensions and relaxation of 1/5 seconds for 3 minutes in total for each arm. Subjects will be instructed to report immediately if the manual treatment starts to induce an increase in symptoms
Study NCT03731975 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CTZ Paste
Description: Tooth allocated to this group will be treated with CTZ paste, according to the Cappielo's protocol (1964), updated by Moura et al. (2016).
Study NCT03731975 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GP Paste
Description: Tooth allocated to this group will be treated with Guedes-Pinto paste, according to the Guedes-Pinto's protocol (1981), updated by Mello-Moura et al. (2011).
Study NCT02274311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate
Description: Clomiphene citrate, 50 mg, orally for three months
Study NCT03175159 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMPACT
Description: Ten counseling sessions
Study NCT03175159 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Two counseling sessions
Study NCT00822120 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bleomycin sulfate
Study NCT00822120 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bleomycin sulfate
Study NCT01731808 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing counseling
Description: The participants who were randomized in the intervention group received outpatient physician-prescribed wound care. Additionally, they received standardized education regarding diabetic foot care. The nurse-led outpatient intervention started a few days after randomization and went on for five weeks. The study nurses conducting the interventions were wound care nurses and trained in foot examination, foot care, education, and counseling. During a period of five weeks, the participants were provided with weekly, one-hour education, skill training, and counseling sessions on foot care. Each participant received a foot care kit with essential foot care material and a foot care diary.
Study NCT01261494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFT505 80mg
Description: hard gelatin capsules dosed at 20mg,oral administration,4 capsules per day before breakfast
Study NCT01261494 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: hard gelatin capsules,oral administration,4 capsules per day before breakfast
Study NCT03614702 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1-dose cIPV + 2-doses bOPV (Candy)
Description: Health subjects received 1-dose cIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Candy) through mouth at 0, 28, 56 days schedule.
Study NCT03614702 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1-dose sIPV + 2-doses bOPV (Candy)
Description: Health subjects received 1-dose sIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Candy) through mouth at 0, 28, 56 days schedule.
Study NCT03614702 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2-doses cIPV + 1-dose bOPV (Candy)
Description: Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Candy) through mouth at 0, 28, 56 days schedule.
Study NCT03614702 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2-doses sIPV + 1-dose bOPV (Candy)
Description: Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Candy) through mouth at 0, 28, 56 days schedule.
Study NCT03614702 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2-doses cIPV + 1-dose tOPV (Candy)
Description: Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Candy) through mouth at 0, 28, 56 days schedule.
Study NCT03614702 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2-doses sIPV + 1-dose tOPV (Candy)
Description: Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Candy) through mouth at 0, 28, 56 days schedule.
Study NCT03614702 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1-dose cIPV + 2-doses bOPV (Liquid)
Description: Health subjects received 1-dose cIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
Study NCT03614702 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1-dose sIPV + 2-doses bOPV (Liquid)
Description: Health subjects received 1-dose sIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
Study NCT03267433 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT
Study NCT03267433 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET or PET/CT
Study NCT03267433 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT03267433 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab and Hyaluronidase Human
Description: Given SC
Study NCT04019288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batiraxcept
Description: Given IV
Study NCT04019288 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT03142841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RESCUE Problem Solving Intervention
Description: This is an education and support intervention for caregivers of Veterans with stroke. The investigators will teach study participants about the COPE model of problem solving and guide them through the application of this model in their caregiver role. They will receive tailored stroke education.
Study NCT02982772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination Therapy
Description: Brief behavioral intervention~The test product is a transdermal nicotine patch for 12 weeks. The dosage of the test product depends on the new algorithm (amount, addiction, prior attempts) Nicotine Gums for 12 weeks.
Study NCT00812578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 8 tablets equivalent to 280 micrograms for 2 weeks and 4 tablets equivalent to 140 micrograms for 10 weeks
Study NCT00812578 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cholecalciferol
Description: 8 tablets equivalent to 280 micrograms for 2 weeks and 4 tablets equivalent to 140 micrograms for 10 weeks
Study NCT03292588 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Mepolizumab administered every 4 weeks by subcutaneous injection at a dose of:~* 100 mg for participants ≥12 years of age and~* 40 mg for participants ages 6 to 11 years and weighing ≥40 kg.~Note: Participants 6 to 11 years of age and weighing ≥40 kg who were enrolled in the study under previous versions of the protocol and were initially assigned a 100 mg dose will have their dose reduced to 40 mg.~Participants 11 years of age will increase to the 100 mg dose if they become age 12 years during the study.
Study NCT03292588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered every 4 weeks by subcutaneous injection at a dose of:~* 100 mg for participants ≥12 years of age and~* 40 mg for participants ages 6 to 11 years and weighing ≥40 kg.~Note: Participants 6 to 11 years of age and weighing ≥40 kg who were enrolled in the study under previous versions of the protocol and were initially assigned a 100 mg dose will have their dose reduced to 40 mg.~Participants 11 years of age will increase to the 100 mg dose if they become age 12 years during the study.
Study NCT00765050 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD133+ cells transplant
Description: intramuscular administration of CD133+ cells that have been mobilized from peripheral blood.
Study NCT00592384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venlafaxine XR
Description: Once daily oral dose of venlafaxine XR ranging from 37.5 mg up to 300 mg
Study NCT00592384 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Once daily oral dose of placebo ranging from 37.5 mg up to 300 mg
Study NCT03527277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Naturally-sweetened orange juice
Description: Commercially-available ready-to-serve refrigerated orange juice
Study NCT03527277 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sugar-sweetened beverage
Description: Sugar-sweetened water flavored with Kool-Aid (TM)
Study NCT00062374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT00062374 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo FDG and FLT PET/CT
Study NCT00062374 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG-PET/CT
Study NCT00062374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluorothymidine F-18
Description: Undergo FLT-PET/CT
Study NCT03614702 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2-doses cIPV + 1-dose bOPV (Liquid)
Description: Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
Study NCT03614702 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2-doses sIPV + 1-dose bOPV (Liquid)
Description: Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
Study NCT03614702 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2-doses cIPV + 1-dose tOPV (Liquid)
Description: Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Liquid) through mouth at 0, 28, 56 days schedule.
Study NCT00062374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study NCT00062374 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG and FLT PET/CT
Study NCT00062374 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo radical subtotal or total gastrectomy with lymph node dissection
Study NCT04078113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pupillometer
Description: Measurements of pupillary dilatation with pupillometer to administer or not analgesia
Study NCT03239288 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control digestible carbohydrate
Description: Single serving of control product
Study NCT03239288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test resistant starch type 4
Description: Single serving of test product
Study NCT03167840 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical and Cognitive Training
Description: Physical Exercise and Cognitive Training
Study NCT03167840 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Training
Description: Physical training alone
Study NCT03167840 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Cognitive training alone
Study NCT02014597 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HOCD
Description: feasibility of HOCD and comparison of HOCD results between subjects with and without glaucoma
Study NCT01604174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive Virtual Telerehabilitation (IVT)
Description: Rehabilitation after arthroplasty of knee using IVT
Study NCT01604174 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care rehabilitation
Description: Standard care rehabilitation after total knee arthroplasty
Study NCT04817865 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Multiplex-PCR with Pooled Antibiotic Susceptibility Testing (M-PCR/P-AST)
Description: M-PCR/P-AST is a dual assessment test that detects pathogenic DNA commonly associated with urinary tract infections and identifies their genotypic and phenotypic antibiotic resistance.
Study NCT04817865 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urine Culture
Description: A traditional clinical UTI evaluation consisting of non-molecular standard urine culture (SUC) and sensitivity testing methods.
Study NCT02338440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lipoprostaglandin E1
Description: Blood sampling before administration (baseline), between 1 hour to 72 hours from administration (plateau 1), 72 hours after engraftment (plateau 2), when the clinician determine to do blood sampling because of change of kidney/liver function change (optional 1), 72 hours from the change of lipoprostaglandin E1 concentration change (optional 2)
Study NCT01432080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 0.75 mg/kg actual body weight/day PO for 7 days followed by a 7 day taper.
Study NCT01432080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin 250 mg PO daily for 2 weeks, then 3 times per week until 3 months
Study NCT01432080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Montelukast 10 mg PO qhs for 3 months
Study NCT01432080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort
Description: Symbicort 200/6 mcg, 2 inhalations every 12 hours for 3 months
Study NCT01780636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botulinum toxin
Study NCT04072302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAF156
Description: 100 mg tablet, 20 mg tablet, 50 mg tablet
Study NCT04072302 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mg tablet, 20 mg tablet, 50 mg tablet
Study NCT00253045 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational groups
Description: Motivational interviewing in group format